📰 Nasdaq Prtk News
Page 4 - Nasdaq Prtk News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Prtk. Real-time updates on events, politics, business and more.
September 26, 2022
Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek’s Management Team...
June 13, 2022
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) and IMV (NASDAQ:IMV – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. Analyst Ratings This is a breakdown of current ratings and […]
June 2, 2022
Analysts expect that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) will announce ($0.35) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Paratek Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.34). Paratek Pharmaceuticals reported earnings […]
May 22, 2022
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) and Kintara Therapeutics (NASDAQ:KTRA – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership. Profitability This table compares Paratek Pharmaceuticals and Kintara Therapeutics’ […]
April 23, 2022
Equities research analysts expect that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) will report sales of $27.15 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Paratek Pharmaceuticals’ earnings. The highest sales estimate is $27.30 million and the lowest is $27.00 million. Paratek Pharmaceuticals posted sales of $16.43 million […]
April 10, 2022
Wall Street brokerages expect Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) to post sales of $27.15 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Paratek Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $27.00 million and the highest estimate coming in at $27.30 million. Paratek Pharmaceuticals reported […]
April 5, 2022
A number of firms have modified their ratings and price targets on shares of Paratek Pharmaceuticals (NASDAQ: PRTK) recently: 3/31/2022 – Paratek Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 3/18/2022 – Paratek Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to […]
March 19, 2022
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) had its price target reduced by equities research analysts at HC Wainwright from $27.00 to $22.00 in a note issued to investors on Thursday, The Fly reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Several other research firms have also recently commented on […]
March 16, 2022
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) announced its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.25), Fidelity Earnings reports. During the same period in the previous year, the firm earned ($0.49) EPS. Paratek Pharmaceuticals updated its FY 2022 […]
December 17, 2021
Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) went up by 5.39% from its latest closing price compared to the recent 1-year high of $11.23. The company’s stock price has collected -1.96% of loss in the last five trading sessions. Press Release reported 10 hours ago that China’s National Medical